利奈唑胺联合达托霉素抗突变效能:体外动态模型研究
本研究利用体外动态模型,观察利奈唑胺/达托霉素联合对两株MRSA及其利奈唑胺耐药突变株的富集影响,并测定药代动力学浓度比下的突变预防浓度(MPC)。结果显示联合用药可阻止利奈唑胺耐药菌富集并限制达托霉素耐药突变株富集,其抗突变作用与延长T>MPC相关。
要点
- 联合用药可阻止利奈唑胺耐药金黄色葡萄球菌富集并限制达托霉素耐药突变株富集。
- 联合的抗突变效果归因于两药MPC降低,从而延长T>MPC。
- 按药代动力学浓度比测定的MPC可预测联合抑制耐药突变的效果。
核心结论
- 利奈唑胺/达托霉素联合可抑制金黄色葡萄球菌耐药突变株富集,T>MPC是联合抗突变效能的可靠预测指标。
研究设计与样本
- 体外动态模型研究,使用两株MRSA(ATCC 700699和2061)及其利奈唑胺耐药突变株,模拟治疗及亚治疗AUC24。
主要发现
- 单药治疗时利奈唑胺耐药突变株在治疗及亚治疗AUC24下均增加,达托霉素耐药突变株仅在亚治疗AUC24下富集。
- 联合用药阻止利奈唑胺耐药金黄色葡萄球菌富集并限制达托霉素耐药突变株富集。
关键数值与推荐
- 联合MPC在利奈唑胺与达托霉素浓度比1:2(对应模拟的AUC24比)下测定。
- 利奈唑胺耐药突变株补充的突变频率为10^-8。
临床怎么用
- 联合用药可考虑用于抑制金黄色葡萄球菌耐药突变富集,MPC及T>MPC有助于预测联合抗突变效果。
局限性
- 研究为体外动态模型,结论需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To explore whether linezolid/daptomycin combinations can restrict Staphylococcus aureus resistance and if this restriction is associated with changes in the mutant prevention concentrations (MPCs) of the antibiotics in combination, the enrichment of resistant mutants was studied in an in vitro dynamic model. METHODS: Two MRSA strains, vancomycin-intermediate resistant ATCC 700699 and vancomycin-susceptible 2061 (both susceptible to linezolid and daptomycin), and their linezolid-resistant mutants selected by passaging on antibiotic-containing medium were used in the study. MPCs of antibiotics in combination were determined at a linezolid-to-daptomycin concentration ratio (1:2) that corresponds to the ratio of 24 h AUCs (AUC24s) actually used in the pharmacokinetic simulations. Each S. aureus strain was supplemented with respective linezolid-resistant mutants (mutation frequency 10-8) and treated with twice-daily linezolid and once-daily daptomycin, alone and in combination, simulated at therapeutic and sub-therapeutic AUC24s. RESULTS: Numbers of linezolid-resistant mutants increased at therapeutic and sub-therapeutic AUC24s, whereas daptomycin-resistant mutants were enriched only at sub-therapeutic AUC24 in single drug treatments. Linezolid/daptomycin combinations prevented the enrichment of linezolid-resistant S. aureus and restricted the enrichment of daptomycin-resistant mutants. The pronounced anti-mutant effects of the combinations were attributed to lengthening the time above MPC of both linezolid and daptomycin as their MPCs were lowered. CONCLUSIONS: The present study suggests that (i) the inhibition of S. aureus resistant mutants using linezolid/daptomycin combinations can be predicted by MPCs determined at pharmacokinetically derived antibiotic concentration ratios and (ii) T>MPC is a reliable predictor of the anti-mutant efficacy of antibiotic combinations as studied using in vitro dynamic models.
引用
- Zinner SH, Alieva KN, Golikova MV, et al. Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. J Antimicrob Chemother. 2021. PMID: 33907810. doi:10.1093/jac/dkab095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。